Journal of nuclear medicine technology最新文献

The emergence of ChatGPT has challenged academic integrity in teaching institutions, including those providing nuclear medicine training. Although previous evaluations of ChatGPT have suggested a limited scope for academic writing, the March 2023 release of generative pretrained transformer (GPT)-4 promises enhanced capabilities that require evaluation. Methods: Examinations (final and calculation) and written assignments for nuclear medicine subjects were tested using GPT-3.5 and GPT-4. GPT-3.5 and GPT-4 responses were evaluated by Turnitin software for artificial intelligence scores, marked against standardized rubrics, and compared with the mean performance of student cohorts. Results: ChatGPT powered by GPT-3.5 performed poorly in calculation examinations (31.4%), compared with GPT-4 (59.1%). GPT-3.5 failed each of 3 written tasks (39.9%), whereas GPT-4 passed each task (56.3%). Conclusion: Although GPT-3.5 poses a minimal risk to academic integrity, its usefulness as a cheating tool can be significantly enhanced by GPT-4 but remains prone to hallucination and fabrication.

As molecular therapy continues to grow, unanticipated challenges may arise, requiring the institution's therapeutic team to reevaluate its therapeutic protocol to identify and address potential situations and challenges that may occur. This practical pointer will focus on the novel prostate cancer therapy Pluvicto (¹⁷⁷Lu-vipivotide tetraxetan) and 2 unique situations and challenges of treating patients at the Theranostic Center at Carilion Clinic, an outpatient facility dedicated to targeted molecular therapy.

The clinical utility of ¹⁸F-FDG PET/CT is being increasingly recognized in histiocytic disorders. We report the case of a 23-y-old woman who presented with slowly progressive, yellowish-brown papules, plaques, and nodules over her face and flexures. Besides the multiple cutaneous lesions, lesions of the brain, stomach, gallbladder, and marrow were additionally revealed by baseline ¹⁸F-FDG PET/CT. Skin biopsy and the overall clinical picture were consistent with xanthoma disseminatum. Subsequent PET/CT after cladribine therapy revealed a decrease in the extent and metabolic activity of most lesions, suggestive of a favorable response. This case report highlights the potential role of ¹⁸F-FDG PET/CT in the accurate assessment of disease extent and posttreatment response in rare histiocytic disorders.

With an aging U.S. population, advancements in the treatment of Alzheimer disease (AD) and other neurodegenerative diseases are key to the maximization of health span. The recent approval of 2 antiamyloid antibodies, which decrease brain amyloid load, places us on the cusp of breakthrough therapies that target the mechanism of the disease rather than just treating the symptoms. Although the trials that led to these approvals studied patients with mild early symptoms, multiple ongoing trials have enrolled cognitively normal patients screened for AD biomarkers including risk factors for amyloid positivity, family history, and genetic markers. Thus, amyloid PET can help identify an at-risk population that can be enrolled for antiamyloid therapy to prevent AD symptoms from ever developing. In this review, we examine the paradigm of neurotheranostics and how PET biomarkers of amyloid, tau, inflammation, and neurodegeneration could characterize the pathologic stage of AD and therefore allow for personalized therapy.

Metastases to the female genital tract are rare, especially from extragenital primaries. The most common extragenital sites associated with genital metastasis are the gastrointestinal tract (37.6%) followed by the breast (34.9%). It is crucial to differentiate primary from metastatic involvement of the uterus for appropriate patient management. We present one such case of endometrial metastasis in a patient who presented clinically with abnormal uterine bleeding and was diagnosed with primary breast cancer via ¹⁸F-FDG PET/CT.

Pheochromocytoma and paraganglioma are rare in children, at only 1 in every 50,000 cases. Even though some cases are sporadic, they have been connected to syndromes such as von Hippel-Lindau, multiple endocrine neoplasia types IIa and IIb, neurofibromatosis type 1, and hereditary pheochromocytoma-paraganglioma syndromes. A genetic mutation causes around 60% of pheochromocytomas and paragangliomas in children under 18. Methods: A 15-y-old child with a 6-y history of back discomfort is presented. The justification for using 2 functional imaging modalities, ⁶⁸Ga-DOTATATE PET/CT and ¹²³I-meta-iodobenzylguanidine SPECT/CT, is examined in this case study. We reviewed the patients' journey since the first referral for imaging. Results: Delaying the molecular imaging modalities has affected patients' overall diagnosis and applied treatment outcomes. Conclusion: This case study investigates the potential for the earlier use of various diagnostic modalities in conjunction with diagnostic testing to facilitate an earlier diagnosis. However, since this study is based solely on imaging and lacks access to the patient's clinical or family history, factors such as potential inequities in health-care facilities, health literacy, and socioeconomic status are not addressed. It is essential to acknowledge these influences as they contribute to the inequitable access to health-care settings in New Zealand.

Clinical imaging research is a fast-growing, complex, and integral part of drug and therapy discovery and development. Research sponsors rely on outside vendors to manage their trials and deliver results they hope will demonstrate the efficacy of their product. Specialized vendors known as imaging contract research organizations have teams of highly trained and specialized professionals who lend their expertise to all aspects of imaging research management, of which nuclear medicine technologists are key team members. This article is part of the Clinical Trials Network Research Series for Technologists and will help provide an overview of an imaging research study from initiation to data delivery and the roles that nuclear medicine technologists and other imaging professionals play.

Presenting an abstract at the Society of Nuclear Medicine and Molecular Imaging annual meeting is an opportunity to gain peer recognition and share knowledge. This article explains how to craft a winning conference abstract. The goal of an abstract is to summarize the main points of a research project or topic. There are 2 types of abstracts: scientific and educational. Scientific abstracts generally involve data collection or a survey and follow a specific formula. The introduction provides a brief background and states the research question. The methods describe the study design and variables. The results present key findings, and the conclusion summarizes the findings' implications and significance. Educational abstracts are unstructured and usually describe a single topic, such as a case study, literature review, or new technique. Crafting an abstract requires clear communication, attention to detail, and an emphasis on practical applications. Effectively structuring a compelling abstract increases your abstract's acceptance chances.